ΒΙΟΓΡΑΦΙΚΟ ΣΗΜΕΙΩΜΑ...- 5 - 2. ΑΠΑΣΧΟΛΗΣΗ – ΔΙΟΙΚΗΤΙΚΗ...

Β Ι Ο Γ Ρ Α Φ Ι Κ Ο Σ Η Μ Ε Ι Ω Μ Α

ΜΑΝΙΑΔΑΚΗΣ ΝΙΚΟΛΑΟΣ

Καθηγητής Διοίκησης και Οργάνωσης Υπηρεσιών Υγείας

Αναπληρωτής Κοσμήτορας

Εθνική Σχολή Δημόσιας Υγείας

Λεωφόρος Αλεξάνδρας 196, Αθήνα 11521

Email:[email protected]

Skype: nikosmaniadakis

Tηλ: +306945237716

Αθήνα, Οκτώβριος - 2017

mailto:[email protected]

- 2 -

ΠΕΡΙΕΧΟΜΕΝΑ

1. ΠΡΟΣΩΠΙΚΑ ΣΤΟΙΧΕΙΑ - ΕΚΠΑΙΔΕΥΣΗ ..................................................................................................... - 3 -

1.1 ΠΡΟΣΩΠΙΚΑ ΣΤΟΙΧΕΙΑ: ................................................................................................................................ - 3 - 1.2 ΠΑΝΕΠΙΣΤΗΜΙΑΚΗ ΕΚΠΑΙΔΕΥΣΗ: ............................................................................................................ - 3 - 1.4 ΣΕΜΙΝΑΡΙΑ ΕΞΕΙΔΙΚΕΥΣΗΣ: ....................................................................................................................... - 4 -

2. ΑΠΑΣΧΟΛΗΣΗ – ΔΙΟΙΚΗΤΙΚΗ ΕΜΠΕΙΡΙΑ .................................................................................................. - 5 -

2.1 ΑΠΑΣΧΟΛΗΣΗ ΣΤΗΝ ΕΛΛΑΔΑ: .................................................................................................................. - 5 - 2.2 ΑΠΑΣΧΟΛΗΣΗ ΣΤΟ ΕΞΩΤΕΡΙΚΟ: ............................................................................................................... - 5 - 2.3 ΣΤΡΑΤΙΩΤΙΚΗ ΘΗΤΕΙΑ:................................................................................................................................. - 5 - 2.4 ΠΑΡΑΛΛΗΛΕΣ ΔΡΑΣΤΗΡΙΟΤΗΤΕΣ: ........................................................................................................... - 5 -

3. ΔΙΔΑΚΤΙΚΟ ΕΡΓΟ ................................................................................................................................................ - 6 -

3.1 AYTONOMH ΔΙΔΑΣΚΑΛΙΑ ΣΕ ΜΕΤΑΠΤΥΧΙΑΚΑ ΠΡΟΓΡΑΜΜΑ ΣΠΟΥΔΩΝ: ..................................... - 6 - 3.2 ΔΙΑΛΕΞΕΙΣ ΣΕ ΜΕΤΑΠΤΥΧΙΑΚΑ ΠΡΟΓΡΑΜΜΑ ΣΠΟΥΔΩΝ: ................................................................. - 6 - 3.3 ΑΥΤΟΝΟΜΗ ΔΙΔΑΣΚΑΛΙΑ ΣΕ ΠΡΟΠΤΥΧΙΑΚΑ ΠΡΟΓΡΑΜΜΑ ΣΠΟΥΔΩΝ: ........................................ - 7 - 3.5 ΣΥΝ-ΕΠΙΒΛΕΨΗ ΜΕΤΑΠΤΥΧΙΑΚΩΝ ΦΟΙΤΗΤΩΝ: ................................................................................... - 7 -

4. ΕΡΕΥΝΗΤΙΚΗ ΔΡΑΣΤΗΡΙΟΤΗΤΑ ΕΣΔΥ 2009 - ............................................................................................. - 7 -

4.1 ΕΠΙΣΤΗΜΟΝΙΚΟΣ ΥΠΕΥΘΥΝΟΣ ΕΡΕΥΝΗΤΙΚΩΝ ΠΡΟΓΡΑΜΜΑΤΩΝ : ................................................ - 7 - 4.2 ΣΥMΜETOXH ΣΕ ΔΙΕΘΝΗ ΕΡΕΥΝΗΤΙΚΑ ΠΡΟΓΡΑΜΜΑΤΑ: .................................................................. - 8 -

5. ΔHMΟΣΙΕΥΣΕΙΣ ................................................................................................................................................... - 8 -

5.1 ΣΥΜΜΕΤΟΧΗ ΣΤΗΝ EΚΔΟΤΙΚΗ ΟΜΑΔΑ: ................................................................................................ - 8 - 5.2 ΔΗΜΟΣΙΕΥΣΕΙΣ ΣΕ ΠΕΡΙΟΔΙΚΑ ΜΕ ΑΞΙΟΛΟΓΗΣΗ: (112) ....................................................................... - 8 - 5.3 ΑΡΘΡΑ ΣTA ΕΛΛΗΝΙΚΑ ΣΕ ΕΠΙΣΤΗΜΟΝΙΚΑ ΠΕΡΙΟΔΙΚΑ ΜΕ ΚΡΙΣΗ: (4) ......................................... - 20 - 5.4 ΜΟΝΟΓΡΑΦΙΕΣ ΣΤΑ ΑΓΓΛΙΚΑ ΣΕ ΔΙΕΘΝΕΙΣ ΣΕΙΡΕΣ ΜΕ ΚΡΙΣΗ: (7) .................................................. - 21 - 5.5 ΚΕΦΑΛΑΙΑ ΣΕ ΕΛΛΗΝΙΚΑ ΒΙΒΛΙΑ: (3) .................................................................................................... - 21 - 5.6 ΚΕΦΑΛΑΙΑ ΣΕ ΔΙΕΘΝΗ ΒΙΒΛΙΑ: (1) .......................................................................................................... - 22 - 5.7 ΔΗΜΟΣΙΕΥΣΕΙΣ ΠΕΡΙΛΗΨΕΩΝ ΣΕ TOMOYΣ ΔΙΕΘΝΩΝ ΣΥΝΕΔΡΙΩΝ: (130) ...................................... - 22 -

6. ΣΥΜΜΕΤΟΧΗ ΣΕ ΣΥΝΕΔΡΙΑ KAI ΕΠΙΤΡΟΠΕΣ ........................................................................................ - 33 -

6.1 ΜΕΛΟΣ ΣΕ ΕΠΙΤΡΟΠΕΣ ΕΜΠΕΙΡΟΓΝΩΜΟΝΩΝ: .................................................................................... - 33 - 6.2 ΣΥΜΜΕΤΟΧΗ ΣΕ ΣΥΝΕΔΡΙΑ: 2009 - .......................................................................................................... - 34 -

- 3 -

1. ΠΡΟΣΩΠΙΚΑ ΣΤΟΙΧΕΙΑ - ΕΚΠΑΙΔΕΥΣΗ

1.1 ΠΡΟΣΩΠΙΚΑ ΣΤΟΙΧΕΙΑ:

Όνομα: Νικόλαος

Επώνυμο: Μανιαδάκης

Όνομα Πατρός: Γεώργιος

Όνομα Μητρός: Ευθαλία

Ημερομηνία Γέννησης: 9 Νοεμβρίου 1968

Τόπος Γέννησης: Ιεράπετρα Κρήτης

Υπηκοότητα : Ελληνική και Αγγλική

Οικογενειακή Κατάσταση: Έγγαμος με δυο παιδιά

Γλώσσες: Ελληνική, Αγγλική

1.2 ΠΑΝΕΠΙΣΤΗΜΙΑΚΗ ΕΚΠΑΙΔΕΥΣΗ:

Διδακτορικό στις Βιομηχανικές και Επιχειρησιακές Σπουδές (Ph.D in Industrial & Business Studies), 1995/96-1997/98, Σχολή Διοίκησης Γουώρικ (Warwick Business School),

Πανεπιστήμιο Γουώρικ (University of Warwick), Κόβεντρυ, Ηνωμένο Βασίλειο.

Με υποτροφία του ΙΚΥ και του Βρετανικού Συμβουλίου.

Θέμα Διατριβής: «Ένας Malmquist Δείκτης Κόστους Εφαρμοσμένος Στην Μέτρηση της

Παραγωγικότητας και της Οργάνωσης των Υπηρεσιών Υγείας»

Μάστερ στα Οικονομικά και τα Οικονομικά της Υγείας (M.Sc in Health Economics), 1994/95, Τμήμα Οικονομικών Σπουδών (Department of Economics), Πανεπιστήμιο Γιόρκ

(University of York), Γιόρκ, Ηνωμένο Βασίλειο

Με υποτροφία του ΙΚΥ.

Θέμα Διατριβής: «Θεωρία και Εφαρμογές Μέτρησης της Παραγωγικότητας και Οργάνωσης

των Υπηρεσιών Υγείας»

Πτυχίο Οικονομικών Σπουδών (Λίαν Καλώς, ανώτατο 3%), 1986/97 – 1990/91, Τμήμα Οικονομικών Επιστημών, Σχολή Νομικών, Οικονομικών & Πολιτικών Επιστημών, Εθνικό και

Καποδιστριακό Πανεπιστήμιο Αθηνών, Αθήνα, Ελλάδα.

1.3 ΣΧΟΛΙΚΗ ΕΚΠΑΙΔΕΥΣΗ:

Απολυτήριο Λυκείου (Άριστα), 1983/84 -1985/86, 1ο Γενικό Λύκειο Ιεράπετρας, Λασίθι, Κρήτης

- 4 -

1.4 ΣΕΜΙΝΑΡΙΑ ΕΞΕΙΔΙΚΕΥΣΗΣ:

Εντατικό Σεμινάριο Οργάνωσης Υπηρεσιών Υγείας στην Βάση της Αξίας (Intensive Value Based Health Care Seminar), by Prof. M Porter, Σχολή Διοίκησης Πανεπιστημίου Χάρβαρντ

(Harvard Business School), 4-8 Ιανουάριος 2016, Μασαχουσέτη, ΗΠΑ

Σεμινάριο, για Ανώτατα Στελέχη, Καινοτομίας και Ηγεσίας για το Μέλλον των Υπηρεσιών Υγείας (Innovating Health tor Tomorrow Executive Programme, Health Care Leadership),

INSEAD, Ιανουάριος 26-30, Mάιος ς 2015, Φοτανεμπλώ, Γαλλία

Με υποτροφία του INSEAD.

Σεμινάριο ΗΠΑ και Ευρώπης Καινοτομίας στην Πολιτική Υγείας (US European Health Policy Innovation Seminar, Transatlantic Health Policy) Πανεπιστήμιο Χάρβαρντ (Harvard

University), Ιανουάριος 3-5 2011, Μασαχουσέτη, ΗΠΑ

Με υποτροφία του Harvard.

Σεμινάριο Ηγεσίας και Συναισθηματικής Νοημοσύνης (Primal Leadership. Learning to Lead with Emotional Intelligence) by Dr. D. Coleman, Αθήνα 6 Ιουνίου 2006

Σεμινάριο Διαχείρισης Αλλαγής (Leading Change. Wat Leader Do) by Dr. J. Kotter, Αθήνα 19 Οκτωβρίου 2005

Δίπλωμα Ανεπτυγμένων Ποσοτικών Μεθόδων Φαρμακοοικονομικού Προγραμματισμού, 9 Νοεμβρίου 2003, Διεθνής Επιστημονική Εταιρεία Έρευνας στην Φαρμακοοικονομία και την

Υγεία (International Society for Pharmacoeconomic and Outcomes Research), Bαρκελώνη,

Ισπανία

Δίπλωμα σε Ανεπτυγμένες Μεθόδους Αξιολόγησης Υπηρεσιών Υγείας, 9 -12 Δεκεμβρίου 2000, Ινστιτούτο Επιστημών Υγείας (Institute of Health Sciences), Πανεπιστήμιο της Οξφόρδης

(University of Oxford), Οξφόρδη, Ηνωμένο Βασίλειο

Δίπλωμα Επιχειρηματικής Εξειδίκευσης (Ανώτατο 5%), 21 Σεπτεμβρίου - 22 Δεκεμβρίου 1992, Τμήμα Οικονομικών Επιστημών Πανεπιστήμιο Αθηνών και Σχολή Διοίκησης,

Πανεπιστήμιο Στέρλινγκ, Σκωτία

Θέμα Διατριβής: «Ο Τομέας Υγείας στην Ελλάδα»

Magista Erasmus – Tempus Program Κοινωνική Ασφάλιση στην Ευρώπη (Διάκριση) (Certificate in Social Security Studies in Europe) 1990/91, Τμήμα Οικονομικών Επιστημών

(Department of Economics), Πανεπιστήμιο Ροσκίλντε (Roskilde University), Ροσκίλντε, Δανία.

Με υποτροφία του IKY

Θέμα Διατριβής: «Η Παραοικονομία στην Παροχή Υπηρεσιών Υγείας»

https://www.linkedin.com/vsearch/p?keywords=Transatlantic+Health+Policy&trk=prof-edu-field_of_study

- 5 -

2. ΑΠΑΣΧΟΛΗΣΗ – ΔΙΟΙΚΗΤΙΚΗ ΕΜΠΕΙΡΙΑ

2.1 ΑΠΑΣΧΟΛΗΣΗ ΣΤΗΝ ΕΛΛΑΔΑ:

Αναπληρωτής Κοσμήτορας, 2013 – 2019, Εθνική Σχολή Δημόσιας Υγείας, Αθήνα

Καθηγητής και Διευθυντής Τομέα Οργάνωσης και Διοίκησης Υπηρεσιών Υγείας 2009 – Σήμερα, Τομέας Οργάνωσης και Διοίκησης Υπηρεσιών Υγείας, Εθνική Σχολή Δημόσιας

Υγείας, Αθήνα

Διοικητής & Πρόεδρος Διοικητικού Συμβουλίου, 2004 – 2006, Πανεπιστημιακό Γενικό Νοσοκομείο Ηρακλείου, Βούτες, Ηρακλείου.

Διοικητής & Πρόεδρος Διοικητικού Συμβουλίου, 2002 –2004, Πανεπιστημιακό Γενικό Νοσοκομείο Πατρών, Ρίο Πατρών.

2.2 ΑΠΑΣΧΟΛΗΣΗ ΣΤΟ ΕΞΩΤΕΡΙΚΟ:

Διευθυντής Ερευνητής Οικονομικών Υγείας (Senior Research Scientist of Health Economics), 2000 –2002, Ευρωπαϊκό Ερευνητικό Τμήμα Στρατηγικής Αγορών Υγείας

(European Market Access Strategy Research), Διοίκηση Ευρώπης, Ερευνητικό Κέντρο Λίλλυ

(European Headquarters, Lilly Research Centre), Eli Lilly & Co Ltd, Surrey, Ηνωμένο Βασίλειο

Διευθυντής Έρευνας Αποτελεσμάτων Υγείας (Manager Health Outcomes Research) 1998 –2000, Κέντρο Μελέτης Υπηρεσιών Υγείας Ευρώπης & Αφρικής (Health Services Research,

Europe and Africa Area), Διοίκηση Ευρώπης και Αφρικής, Pharmacia Corp, High Wycombe,

Ηνωμένο Βασίλειο

Ερευνητής Οικονομικών Υγείας (Αssistant Research Fellow), 1996 –1998, Κέντρο Έρευνας Οικονομικών της Υγείας Ινστιτούτο Επιστημών Υγείας και Κολλέγιο Wolfson (Health Services

Research Centre, Institute of Health Science), Πανεπιστήμιο της Οξφόρδης, Οξφόρδη, Ηνωμένο

Βασίλειο.

2.3 ΣΤΡΑΤΙΩΤΙΚΗ ΘΗΤΕΙΑ:

Έφεδρος Αξιωματικός Οικονομικού, Προϊστάμενος Μηχανογράφησης Κεντρικού Ταμείου Στρατού, Ιούνιος 1991 – Δεκέμβριος 1993, Κεντρικό Ταμείο Στρατού, Στρατιωτική Διοίκηση

Αττικής, Υπουργείο Εθνικής Αμύνης, Αθήνα, Ελλάδα.

2.4 ΠΑΡΑΛΛΗΛΕΣ ΔΡΑΣΤΗΡΙΟΤΗΤΕΣ:

Επιστημονικός Συντονιστής, 2010 – Σήμερα, Μονάδα Πολιτικής Υγείας, Ευρωπαϊκή Καρδιολογική Εταιρεία, Βρυξέλες, Βέλγιο

Διευθυντής ΜΠΣ στην Διοίκηση Υπηρεσιών Υγείας, 2009-2017, Εθνική Σχολή Δημόσιας Υγείας

Συνεργαζόμενο Εκπαιδευτικό Προσωπικό, 2008-2011, ΜΠΣ Διοίκησης Υπηρεσιών Υγείας, Ανοικτό Πανεπιστήμιο Κύπρου

- 6 -

Άμισθος Διευθύνων Σύμβουλος, 2004-2006, Εταιρεία Διαχείρισης & Αξιοποίησης της Περιουσίας Πανεπιστημίου Κρήτης

Επισκέπτης Ερευνητής (Associate Fellow), 1998 – 2004, Κέντρο Σπουδών Υπηρεσιών Υγείας (Health Services Research Centre), Σχολή Διοίκησης Επιχειρήσεων (Warwick Business School),

Πανεπιστήμιο Γουώρικ (University of Warwick), Κόβεντρυ, Ηνωμένο Βασίλειο.

Διδάσκων με το Καθεστώς Νόμου 407, 2002/03, Τμήμα Οικονομικών Επιστημών, Πανεπιστήμιο Πατρών, Πάτρα

3. ΔΙΔΑΚΤΙΚΟ ΕΡΓΟ

3.1 AYTONOMH ΔΙΔΑΣΚΑΛΙΑ ΣΕ ΜΕΤΑΠΤΥΧΙΑΚΑ ΠΡΟΓΡΑΜΜΑ ΣΠΟΥΔΩΝ:

Αρχές Διοίκησης και Στρατηγικής Υπηρεσιών Υγείας, 2009 – Σήμερα, ΜΠΣ Διοίκησης Υπηρεσιών Υγείας, Εθνική Σχολή Δημόσιας Υγείας, Αθήνα

Χρηματοοικονομική Ανάλυση και Διαχείριση Υπηρεσιών Υγείας, 2008 – Σήμερα, ΜΠΣ Διοίκησης Υπηρεσιών Υγείας, Εθνική Σχολή Δημόσιας Υγείας, Αθήνα

Οικονομική και Χρηματοδοτική Διαχείριση Υπηρεσιών Υγείας, 2007 – 2010, ΜΠΣ Διοίκησης Μονάδων Υγείας, Ανοικτό Πανεπιστήμιο Κύπρου, Λευκωσία, Κύπρος

Πολιτική Υγείας και Κοινωνικής Προστασίας Στην Ελλάδα και την ΕΕ, 2005, ΜΠΣ Διοίκηση Υγείας, ΤΕΙ και Πανεπιστήμιο Πειραιώς, Αιγάλεω,

Επιχειρησιακή Στρατηγική, 2005-2008, ΜΠΣ Διοίκηση Υγείας, ΤΕΙ και Πανεπιστήμιο Πειραιώς, Αιγάλεω,

Διοίκηση Υπηρεσιών Υγείας, 2009, Μεταπτυχιακό Πρόγραμμα Σπουδών στο Φαρμακευτικό Μάρκετινγκ, Φαρμακευτική Σχολή, Πανεπιστήμιο Πάτρας, Πάτρα

Φαρμακοοικονομία, 2005 - 2007, Μεταπτυχιακό Πρόγραμμα Σπουδών στο Φαρμακευτικό Μάρκετινγκ, Φαρμακευτική Σχολή, Πανεπιστήμιο Πάτρας, Πάτρα

Introduction to Mathematics, 1996 – 1998, M.Sc. in Management Science and Operations Research, Warwick Business School, University of Warwick, United Kingdom

3.2 ΔΙΑΛΕΞΕΙΣ ΣΕ ΜΕΤΑΠΤΥΧΙΑΚΑ ΠΡΟΓΡΑΜΜΑ ΣΠΟΥΔΩΝ:

Economic Evaluation in Health Care, 2016-17, Master of Science (MSc) in Health Economics, Outcomes and Management in Cardiovascular Sciences, London School of Economics,

Health Economics, Diploma of Advanced Studies in Cardiac Arrhythmia Management (DAS-CAM), 2016 – 20017 Maastricht University, Netherlands

- 7 -

Mεθοδολογία Αξιολόγησης & Οργάνωσης Υπηρεσιών Υγείας, 2004-2005, Μεταπτυχιακό Πρόγραμμα Σπουδών Δημόσια Υγεία και Διοίκηση Υπηρεσιών Υγείας, Ιατρική Σχολή,

Πανεπιστήμιο Κρήτης, Ηράκλειο

Αξιολόγηση Υπηρεσιών Υγείας, 2002, ΜΠΣ Διοίκησης Υπηρεσιών Υγείας, Εθνική Σχολή Δημόσιας Διοίκησης, Αθήνα

Health Technology Assessment, 2002-2004, Πρόγραμμα Erasmus Αξιολόγησης Τεχνολογιών Υγείας, Ινστιτούτο Βιοιατρικής Τεχνολογίας, Πανεπιστήμιο Πατρών, Πάτρα

Seminar on Evaluation of Technologies, 2000, Diploma/MSc in Regulatory Affairs, British Institute of Regulatory Affairs and University of Wales, 2001, Cardiff , Wales.

3.3 ΑΥΤΟΝΟΜΗ ΔΙΔΑΣΚΑΛΙΑ ΣΕ ΠΡΟΠΤΥΧΙΑΚΑ ΠΡΟΓΡΑΜΜΑ ΣΠΟΥΔΩΝ:

Οργάνωση και Διοίκηση Επιχειρήσεων, 2002-2003, Πτυχίο Οικονομικών, Τμήμα Οικονομικών, Πανεπιστήμιο Πατρών, Πάτρα

Αξιολόγηση Επενδύσεων, 2002-2003, Πτυχίο Οικονομικών, Τμήμα Οικονομικών, Πανεπιστήμιο Πατρών, Πάτρα.

Quantitative Methods in Economics and Management, 1996 - 1998, B.Sc. in Management Science, Warwick Business School, University of Warwick, United Kingdom.

3.5 ΣΥΝ-ΕΠΙΒΛΕΨΗ ΜΕΤΑΠΤΥΧΙΑΚΩΝ ΦΟΙΤΗΤΩΝ:

Μάστερ: ΜΠΣ Διοίκησης Υπηρεσιών Υγείας ΕΣΔΥ (11), ΜΠΣ Διοίκηση Υγείας Πανεπιστήμιο και ΤΕΙ Πειραιώς (5), M.Sc in Health Policy, London School of Economics (3), ΜΠΣ

Πρόγραμμα Σπουδών Δημόσια Υγεία και Διοίκηση Υπηρεσιών Υγείας, Ιατρική Σχολή,

Πανεπιστήμιο Κρήτης (2)

Διδακτορικό: Ιατρική Σχολή Πανεπιστημίου Κρήτης (2), Νοσηλευτική Σχολή Πανεπιστημίου Αθήνας (3), Ιατρική Σχολή Πανεπιστημίου Αθήνας (1).

4. ΕΡΕΥΝΗΤΙΚΗ ΔΡΑΣΤΗΡΙΟΤΗΤΑ ΕΣΔΥ 2009 -

4.1 ΕΠΙΣΤΗΜΟΝΙΚΟΣ ΥΠΕΥΘΥΝΟΣ ΕΡΕΥΝΗΤΙΚΩΝ ΠΡΟΓΡΑΜΜΑΤΩΝ :

Ιδιωτική χρηματοδότηση: συνολικά 62 έργα προϋπολογισμού € 4.9 εκατομμύριων σε θέματα οικονομική αξιολόγησης, πολιτικής και διοίκησης υπηρεσιών υγείας.

Δημόσια χρηματοδότηση: συνολικά από ΕΣΠΑ 3 έργα € 3.6 Εκατομμυρίων Ευρώ σε θέματα οργάνωση, πολιτική και διοίκησης υπηρεσιών υγείας

Επιλεγμένα έργα και μελέτες Εθνικού βεληνεκούς: α.) Μελέτη και εφαρμογή των DRGs για την αποζημίωση των νοσοκομείων στην Ελλάδα (2011), β.) Μελέτη και εφαρμογή για την

χρήση αναλυτικής λογιστικής και διπλογραφικού στα δημόσια νοσοκομεία (2011). γ.) Μέτρηση

και ανάλυση παραγωγικότητας των νοσοκομείων του ΕΣΥ (2010), δ.) Μέτρηση εθνικού

κόστους αθηροσκλήρωσης, άσθματος, χρόνιας αποφρακτικής πνευμονοπάθειας.

- 8 -

4.2 ΣΥMΜETOXH ΣΕ ΔΙΕΘΝΗ ΕΡΕΥΝΗΤΙΚΑ ΠΡΟΓΡΑΜΜΑΤΑ:

BigData&Heart (2017-2022), Work Package 3 Co-Leader of IMI2, undertaken by several academic and industry partners including Harvard-Karolinska-BCG ICHOM, UCL, Cambridge,

ESC, Utrecht and other universities. Funded by EU and EFPIA with 20 million.

European Atlas of Cardiology (2010-2018) designed and completed the ESC European Atlas of cardiology for 56 countries; Funded by the European Society of Cardiolog.

CATH ME (Characterizing Atrial Fibrillation by Translating its caused into health modifies in the Elderly (2015-2019). Responsible for health economics and policy module. A Horizon 2020

project. Funded by EU with 5 million.

5. ΔHMΟΣΙΕΥΣΕΙΣ

5.1 ΣΥΜΜΕΤΟΧΗ ΣΤΗΝ EΚΔΟΤΙΚΗ ΟΜΑΔΑ:

Αssociate Editor: Applied Health Economics and Policy, https://link.springer.com/ journal / 40258

Editorial Board Member: PharmacoEconomics, https://link.springer.com/ journal/ 40273

Referee: Applied Economics, Health Economics, Medical Economics, Pharmacoeconomics, Applied Health Economics and Policy, Health Economics and Policy Review, European Journal

of Health Economics, Social Science, Clinical Economics and Outcomes Research, European

Journal of Operational Research, Journal of Health Care Management Science, Journal of the

Operational Research Society, Operational Research: an International Journal, Journal of

Productivity Analysis, Journal of Performance Management, Journal of Outcomes and Disease

Management, International Journal of Outcomes Research, Drug, Drug Therapy, British Journal

of Clinical Oncology, Therapeutics and Clinical Research, Pain, Outcomes Research,

Pharmacology, Diabetic Medicine, Cancer Treatments Reviews, Breast Cancer, British Journal

of Cancer, Oncology, Lung Cancer, Acta Oncologica, BMJ, Pharmacology, Breast, Lancet,

JAMA.

5.2 ΔΗΜΟΣΙΕΥΣΕΙΣ ΣΕ ΠΕΡΙΟΔΙΚΑ ΜΕ ΑΞΙΟΛΟΓΗΣΗ: (112)

Άρθρα: 122

Αναφορές (citations): 3844

Συντελεστής Επίπτωσης (impact factor): 709

H index: 24

Van Hagen I, Hall R, Baart S, Maggioni A, Tavazzi L, Bartolomei B, Lelonek M, Johnson M, Maniadakis N, et al. Influence of socioeconomic factors on pregnancy outcome in women with

structural heart disease. Heart (accepted)

Impact Factor: 6.059, Citations: .

Timmis A, Townsend N, Gale C, Grobbee D, Maniadakis N, Flather M, Wilkins E, Wright F, Vos R, Bax J, Blum M, Pinto F, Vardas P. European Society of Cardiology: Cardiovascular

Disease Statistics 2017. European Heart Journal, 2017


https://link.springer.com/%20journal%20/%2040258https://link.springer.com/%20journal%20/%2040258https://link.springer.com/

- 9 -

Hemingway H, Asselbergs F, Danesh F, Dobson R, Maniadakis N, et al. Big data from electronic health records for early and late translational cardiovascular research: challenges and

potential European Heart Journal, 2017, ehx487, https://doi.org/10.1093/eurheartj/ehx487


Brixner D, Maniadakis N, Kaló Z, Hu S, Shen J, Wijaya K. Considering Multicriteria Decision Analysis (MCDA) Simple Scoring as an Evidence-Based HTA Methodology for Evaluating Off-

Patent Pharmaceuticals (OPPs) in Emerging Markets, Value in Health Regional Issues, 2017, 13,

1–6

Tzanetakos C, Tzioufas A, Goules A, Kourlaba G, Theodoratou T, Christou P, Maniadakis N. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with

moderate-to-severe active rheumatoid arthritis in Greece. Rheumatol Int. 2017 May 18. doi:

10.1007/s00296-017-3736-z. [Epub ahead of print]


Gourzoulidis G, Kourlaba G, Kakisis J, Matsagkas M, Giannakoulas G, Gourgoulianis KI, Vassilakopoulos T, Maniadakis N. Cost-Effectiveness Analysis of Rivaroxaban for Treatment of

Deep Vein Thrombosis and Pulmonary Embolism in Greece. Clin Drug Investig. 2017 Jun 12.

doi: 10.1007/s40261-017-0540-1. [Epub ahead of print]


Fragoulakis V, Mitropoulou C, Katelidou D, van Schaik RH, Maniadakis N, Patrinos GP.Performance Ratio Based Resource Allocation Decision-Making in Genomic

Medicine.OMICS. 2017 Feb;21(2):67-73. doi: 10.1089/omi.2016.0161. Epub 2017 Jan 24.

Impact Factor: 1.723 Citations: .

Maniadakis N, Kourlaba G, Shen J, Holtorf, A. Comprehensive taxonomy and worldwide trends in pharmaceutical policies in relation to country income status." BMC Health Serv Res, 2017,

17(1): 371.


Stafylas P, Farmakis D, Kourlaba G, Giamouzis G, Tsarouhas K, Maniadakis N, Parissis J. The heart failure pandemic: The clinical and economic burden in Greece. Int J Cardiol, 2017; 227,

923-929.


Farmakis D, Stafylas P, Giamouzis G, Maniadakis N, Parissis J. The medical and socioeconomic burden of heart failure: A comparative delineation with cancer International Journal of

Cardiology 203 (2016) 279–281


Gourzoulidis, G., Kourlaba, G. Stafylas, P. Giamouzis, G. Parissis, J. Maniadakis, N. Association between copayment, medication adherence and outcomes in the management of patients with

diabetes and heart failure. Health Policy, 2017. 121(4): p. 363-377.


Fragoulakis V, Mitropoulou C, Katelidou D, van Schaik, RH, Maniadakis N, Patrinos G. Performance Ratio Based Resource Allocation Decision-Making in Genomic Medicine. OMICS,

2017. 21(2): p. 67-73.


https://doi.org/10.1093/eurheartj/ehx487

- 10 -

Kourlaba G, Gialama F, Tsioufis K, Maniadakis N. A literature review to evaluate the clinical and economic value of olmesartan for the treatment of hypertensive patients. Int J Cardiol. 2016

Jun 24;221:60-74. doi: 10.1016/j.ijcard.2016.06.115. [Epub ahead of print]

Impact Factor: 6.189, Citations: 3.

Kourlaba G, Hillas G, Vassilakopoulos T, Maniadakis N. The disease burden of chronic obstructive pulmonary disease in Greece. Int J Chron Obstruct Pulmon Dis. 2016 Sep 9;11:2179-

2189. eCollection 2016.


Fragoulakis V, Pescott CP, Smeenk JM, van Santbrink EJ, Oosterhuis GJ, Broekmans FJ, Maniadakis N Economic Evaluation of Three Frequently Used Gonadotrophins in Assisted

Reproduction Techniques in the Management of Infertility in the Netherlands. Appl Health Econ

Health Policy. 14(6): p. 719-727.


Tzanetakos C, Tentolouris N, Kourlaba G, Maniadakis N. Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece. Clin Drug

Investig. 2016 Aug;36(8):649-59. doi: 10.1007/s40261-016-0410-2.


Body JJ, Acklin YP, Gunther O, Hechmati G Pereira J, Maniadakis N, Terpos E, Finek J von Moos R, Talbot S, Sleeboom H. Pathologic fracture and healthcare resource utilisation: A

retrospective study in eight European countries. J Bone Oncol, 2016. 5(4): p. 185-193.


Fragoulakis V, Mitropoulou C, van Schaik RH, Maniadakis N, Patrinos GP. An Alternative Methodological Approach for Cost-Effectiveness Analysis and Decision Making in Genomic

Medicine. OMICS. 2016 May;20(5):274-82. doi: 10.1089/omi.2016.0018. Epub 2016 Apr 20.


Kourlaba G, Relakis J, Mahon R, Kalogeropoulou M, Pantelopoulou G, Kousidou O, Maniadakis N. Cost-utility of ranibizumab versus aflibercept for treating Greek patients with visual

impairment due to diabetic macular edema. Cost Eff Resour Alloc. 2016 Apr 14;14:7. doi:

10.1186/s12962-016-0056-


Vellopoulou K, Kourlaba G, Maniadakis N, Vardas P. A literature review to evaluate the economic value of ranolazine for the symptomatic treatment of chronic angina pectoris. Int J

Cardiol. 2016 May 15;211:105-11. doi: 10.1016/j.ijcard.2016.02.140. Epub 2016 Mar 2. Review.


Fanourgiakis J, Simantirakis E, Maniadakis N, Kanoupakis E, Chrysostomakis S, Kourlaba G, Chlouverakis G, Vardas P. Complications Related to Cardiac Rhythm Management Device

Therapy and Their Financial Implication: A Prospective Single-Center TwoYear Survey. Hellenic

J Cardiol. 2016 Jan-Feb;57(1):33-8.


- 11 -

Pereira J, Body JJ, Gunther O, Sleeboom H, Hechmati G, Maniadakis N, Terpos E, Acklin YP, Finek J, von Moos R.Cost of skeletal complications from bone metastases in six European

countries. J Med Econ. 2016 Jun;19(6):611-8. doi: 10.3111/13696998.2016.1150852. Epub 2016

Feb 23.

Impact Factor: -, Citations: 7.

Fabritz L, Guasch E, Antoniades C, Bardinet I, Benninger G, Betts TR, Brand E, Breithardt G, Bucklar-Suchankova G, Camm AJ, Cartlidge D, Casadei B, Chua WW, Crijns HJ, Deeks J,

Hatem S, Hidden-Lucet F, Kääb S, Maniadakis N, Martin S, Mont L, Reinecke H, Sinner MF,

Schotten U, Southwood T, Stoll M, Vardas P, Wakili R, West A, Ziegler A, Kirchhof P. Expert

consensus document: Defining the major health modifiers causing atrial fibrillation: a roadmap to

underpin personalized prevention and treatment. Nat Rev Cardiol. 2016 Apr;13(4):230-7. doi:

10.1038/nrcardio.2015.194. Epub 2015 Dec


Maggioni AP, Van Gool K, Biondi N, Urso R, Klazinga N, Ferrari R, Maniadakis N, Tavazzi L. Appropriateness of Prescriptions of Recommended Treatments in Organisation for Economic Co-

operation and Development Health Systems: Findings Based on the Long-Term Registry of the

European Society of Cardiology on Heart Failure. Value Health. 2015 Dec;18(8):1098-104. doi:

10.1016/j.jval.2015.08.005. Epub 2015 Sep 14.


Kourlaba G, Vlachopoulos C, Parissis J, Kanakakis J, Gourzoulidis G, Maniadakis N. Ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Greece: a cost-utility

study. BMC Health Serv Res. 2015 Dec 18;15:566. doi: 10.1186/s12913-015-1228-y.


Farmakis D, Stafylas P, Giamouzis G, Maniadakis N, Parissis J. The medical and socioeconomic burden of heart failure: A comparative delineation with cancer. Int J Cardiol. 2016 Jan

15;203:279-81. doi: 10.1016/j.ijcard.2015.10.172. Epub 2015 Oct 20.


Thanassoulis, E., Shiraz R, Maniadakis N, A cost Malmquist productivity index capturing group performance. European J Operations Research 2015 241: p. 796-805.


Kourlaba G, Relakis J, Kontodimas S, Holm MV, Maniadakis N. A systematic review and meta-analysis of the epidemiology and burden of venous thromboembolism among pregnant women.

Int J Gynaecol Obstet. 2016 Jan;132(1):4-10. doi: 10.1016/j.ijgo.2015.06.054. Epub 2015 Oct 9.


Kourlaba G, Gourzoulidis G, Andrikopoulos G, Tsioufis K, Beletsi A, Maniadakis N. Economic evaluation of trimetazidine in the management of chronic stable angina in Greece. BMC Health

Services, (2016) 16:520 DOI 10.1186/s12913-016-1779-6


Body JJ, Pereira J, Sleeboom H, Maniadakis N, Terpos E, Acklin YP, Finek J, Gunther O, Hechmati G, Mossman T, Costa L, Rogowski W, Nahi H, von Moos R. Health resource

utilization associated with skeletal-related events: results from a retrospective European study.

Eur J Health Econ. 2016 Jul;17(6):711-21. doi: 10.1007/s10198-015-0716-7. Epub 2015 Aug 8.


- 12 -

Kourlaba G, Rapti V, Alexopoulos A, Relakis J, Koumakis G, Chatzikou M, Maniadakis N, Georgoulias V. Everolimus plus exemestane versus bevacizumab-based chemotherapy for

second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An

economic evaluation study. BMC Health Serv Res. 2015 Aug 5;15:307. doi: 10.1186/s12913-

015-0971-4.


Vardas P, Maniadakis N, Bardinet I, Pinto F. The European Society of Cardiology Atlas of Cardiology: rational, objectives, and methods. European Heart Journal – Quality of Care and

Clinical Outcomes doi:10.1093/ehjqcco/qcv020

Factor: , Citations: 7.

Stafylas P, Kourlaba G, Hatzikou M, Georgiopoulos D, Sarafidis P, Maniadakis N. Economic evaluation of a single-pill triple antihypertensive therapy with valsartan, amlodipine, and

hydrochlorothiazide against its dual components. Cost Eff Resour Alloc 2015;13:10.


Plagisou L, Tsironi M, Zyga S, Moisoglou I, Maniadakis N, Prezerakos P. Assessment of nursing staff's theoretical knowledge of cardiovascular resuscitation in an NHS public hospital. Hellenic J

Cardiol 2015;56(2):149-53.


Kourlaba G, Relakis J, Mylonas C, Kapaki V, Kontodimas S, Holm MV, et al. The humanistic and economic burden of venous thromboembolism in cancer patients: a systematic review. Blood

Coagul Fibrinolysis 2015;26(1):13-31.


Maniadakis N, Fragoulakis V, Mylonas C, Sharma R, Coats A. Economic evaluation of Cardiac Contractility Modulation (CCM) therapy with the optimizer IVs in the management of heart

failure patients International Cardiovascular Forum Journal 4 (2015), DOI:

10.17987/icfj.v4i0.173

Kourlaba G, Dimopoulos MA, Pectasides D, Skarlos DV, Gogas H, Pentheroudakis G, et al. Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of

adjuvant chemotherapy in patients with st cancer. Support Care Cancer 2015;23(7):2045-51.


Fragoulakis V, Vitsou E, Hernandez AC, Maniadakis N. Economic evaluation of anti-TNF agents for patients with rheumatoid arthritis in Greece. Clinicoecon Outcomes Res 2015;7:85-93.


Fragoulakis V, Raptis E, Vitsou E, Maniadakis N. Annual biologic treatment cost for new and existing patients with moderate to severe plaque psoriasis in Greece. Clinicoecon Outcomes Res

2015;7:73-83.


Moisoglou I, Prezerakos P, Galanis P, Siskou O, Maniadakis N, Kaitelidou D , Conflict Management in a Greek Public Hospital: Collaboration or Avoidance? International Journal of

Caring Sciences, 2014, 7, 75-82

Dreliozi A, Siskou O, Maniadakis N, Prezerakos P. Continuing Education and Development Opportunities in Greek Hospitals: Comparison of Perspectives between Nurses and other Health

- 13 -

Professionals. International Journal Of Occupational Health and Public Health Nursing, vol.1,

no. 2, 2014, 3-16

Tzanetakos C, Melidonis A, Verras C, Kourlaba G, Maniadakis N. Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes

on oral antidiabetic drugs in Greece. BMC Health Serv Res 2014;14:419.


Gialama F, Miloni E, Maniadakis N. Cost Effectiveness of Treatments for non-ST-segment elevation Acute Coronary Syndrome. Pharmacoeconomics 2014.


Fragoulakis V, Stamoulis K, Grouzi E, Maniadakis N. The cost of blood collection in Greece: an economic analysis. Clin Ther 2014;36(7):1028-1036 e5.


Kourlaba G, Maniadakis N, Andrikopoulos G, Vardas P. Economic evaluation of rivaroxaban in stroke prevention for patients with atrial fibrillation in Greece. Cost Eff Resour Alloc

2014;12(1):5.


Gialama F, Prezerakos P, Maniadakis N. The cost effectiveness of implantable cardioverter defibrillators: a systematic review of economic evaluations. Appl Health Econ Health Policy

2014;12(1):41-9.


Kourlaba G1, Parissis J, Karavidas A, Beletsi A, Milonas C, Branscombe N, Maniadakis N. Economic evaluation of ivabradine in the treatment of chronic heart failure in Greece. BMC

Health Serv Res. 2014 Dec 11;14:631. doi: 10.1186/s12913-014-0631-0.


Maniadakis N, Kapaki V, Damianidi L, Kourlaba G. A systematic review of the effectiveness of taxes on nonalcoholic beverages and high-in-fat foods as a means to prevent obesity trends.

Clinicoecon Outcomes Res. 2013 Oct 22;5:519-543. Review.


Charalambous C, Maniadakis N, Polyzos N, Fragoulakis V, Theodorou M.The efficiency of the public dental services (PDS) in Cyprus and selected determinants. BMC Health Serv Res. 2013

Oct 18;13(1):420. [Epub ahead of print]


Gialama F, Maniadakis N. Comprehensive overview: efficacy, tolerability, and cost-effectiveness of irbesartan. Vasc Health Risk Manag. 2013;9:575-92. doi: 10.2147/VHRM.S50831. Epub 2013

Oct 7. Review.


Anastasiadis K, Fragoulakis V, Antonitsis P, Maniadakis N. Coronary artery bypass grafting with minimal versus conventional extracorporeal circulation; an economic analysis. Int J Cardiol. 2013

Oct 15;168(6):5336-43. doi: 10.1016/j.ijcard.2013.08.006. Epub 2013 Aug 15.


- 14 -

Andrikopoulos GK, Fragoulakis V, Maniadakis N. Economic evaluation of dabigatran etexilate in the management of atrial fibrillation in Greece. Hellenic J Cardiol. 2013 Jul-Aug;54(4):289-300.


Fragoulakis V, Maniadakis N. Estimating the long-term effects of in vitro fertilization in Greece: an analysis based on a lifetime-investment model. Clinicoecon Outcomes Res. 2013 Jun

20;5:247-55. doi: 10.2147/CEOR.S44784. Print 2013.


Dreliozi A, Siskou O, Maniadakis N, Prezerakos P. Clinical Governance and Effective Quality & Risk Management in Greek Hospitals International Journal of Health Research and Innovation,

vol. 1, no. 3, 2013, 7-17 ISSN: 2051-5057 (print version), 2051-5065 (online)

Kourlaba G, Fragoulakis V, Theodoratou D, Maniadakis N. Economic evaluation of telmisartan, valsartan and losartan in combination with hydrochlorothiazide for treatment of mild-to-moderate

hypertension in Greece: a cost-utility analysis. Journal of Pharmaceutical Health Services

Research. 2013, 4(2), 81–88

Maniadakis N, Kourlaba G, Mougiakos T, Chatzimanolis I, Jonsson L. Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in

Greece. BMC Health Serv Res. 2013 May 10;13(1):173. [Epub ahead of print]


Fragoulakis V, Kastritis E, Psaltopoulou T, Maniadakis N.Economic evaluation of therapies for patients suffering from relapsed-refractory multiple myeloma in Greece. Cancer Manag Res.

2013 Apr 10;5:37-48. doi: 10.2147/CMAR.S43373. Print 2013.


Boriani G, Maniadakis N, Auricchio A, Müller-Riemenschneider F, Fattore G, Leyva F, Mantovani L, Siebert M, Willich SN, Vardas P, Kirchhof P. Health technology assessment in

interventional electrophysiology and device therapy: a position paper of the European Heart

Rhythm Association. Eur Heart J. 2013 Feb 7. [Epub ahead of print]


Theodorou M, Stafylas P, Kourlaba G, Kaitelidou D, Maniadakis N, Papademetriou V. Physicians' perceptions and adherence to guidelines for the management of hypertension: a

national, multicentre, prospective study. Int J Hypertens. 2012;2012:503821. doi:

10.1155/2012/503821. Epub 2012 Nov 28.


Fanourgiakis J, Simantirakis E, Maniadakis N, Kourlaba G, Kanoupakis E, Chrysostomakis S, Vardas P. Cost-of-illness study of patients subjected to cardiac rhythm management devices

implantation: results from a single tertiary centre. Europace. 2013 Mar;15(3):366-75. doi:

10.1093/europace/eus363. Epub 2012 Nov 12.


Panagopoulou P, Gogas H, Dessypris N, Maniadakis N, Fountzilas G, Petridou ET. Survival from breast cancer in relation to access to tertiary healthcare, body mass index, tumor characteristics

and treatment: a Hellenic Cooperative Oncology Group (HeCOG) study. Eur J Epidemiol. 2012

Oct 20. [Epub ahead of print]


- 15 -

Fragoulakis V, Papagiannopoulou V, Kourlaba G, Maniadakis N, Fountzilas G. Cost-minimization analysis of the treatment of patients with metastatic colorectal cancer in Greece.

Clin Ther. 2012 Oct;34(10):2132-42. doi: 10.1016/j.clinthera.2012.09.005.


Fragoulakis V, Kourlaba G, Tarlatzis B, Mastrominas M, Maniadakis N. Economic evaluation of alternative assisted reproduction techniques in management of infertility in Greece. Clinicoecon

Outcomes Res. 2012;4:185-92. Epub 2012 Jul 12.


Kourlaba G, Fragoulakis V, Maniadakis N. Clopidogrel versus aspirin in patients with atherothrombosis: a CAPRIE-based cost-effectiveness model for Greece. Appl Health Econ

Health Policy. 2012 Sep 1;10(5):331-42. doi: 10.2165/11633970-000000000-00000.


Maniadakis N, Kourlaba G, Cokkinos DV, Angeli A, Kyriopoulos J. The economic burden of atherothrombosis in Greece: results from the THESIS study. Eur J Health Econ. 2012 Jul 10.


Fragoulakis V, Kourlaba G, Maniadakis N. Economic evaluation of statins in high-risk patients treated for primary and secondary prevention of cardiovascular disease in Greece. Clinicoecon

Outcomes Res. 2012;4:135-43. Epub 2012 May 29.


Fragoulakis V, Pallis A, Kaitelidou D, Maniadakis N, Georgoulias V. Economic evaluation of pemetrexed versus erlotinib as second-line treatment of patients with advanced/metastatic non-

small cell lung cancer in Greece: a cost minimization analysis. Lung Cancer (Auckl). 2012 Jul

16;3:43-51. doi: 10.2147/LCTT.S33608. eCollection 2012.

Impact Factor: 4.294 , Citations: 2.

Kourlaba G, Fragoulakis V, Maniadakis N. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis. Appl Health

Econ Health Policy. 2012 Jul 1;10(4):261-71. doi: 10.2165/11633820-000000000-00000.


Fragoulakis V, Kourlaba G, Goumenos D, Konstantoulakis M, Maniadakis N. Economic evaluation of intravenous iron treatments in the management of anemia patients in Greece.

Clinicoecon Outcomes Res. 2012;4:127-34. Epub 2012 May 4.


Athanasakis K, Fragoulakis V, Tsiantou V, Masaoutis P, Maniadakis N, Kyriopoulos J.Cost-Effectiveness Analysis of Ranibizumab versus Verteporfin Photodynamic Therapy, egaptanib

Sodium, and Best Supportive Care for the Treatment of Age-Related Macular Degeneration in

Greece. Clin Ther. 2012 Feb;34(2):446-56. Epub 2012 Jan 30.


Liatsikos E, Kyriazis I, Kallidonis P, Sakellaropoulos G, Maniadakis N .Photoselective GreenLight(™) Laser Vaporization Versus Transurethral Resection of the Prostate in Greece: A

Comparative Cost Analysis. J Endourol. 2012 Feb;26(2):168-73. Epub 2011 Nov 11.


- 16 -

Theodorou M, Kaitelidou D, Galanis P, Middleton N, Theodorou P, Stafylas P, Siskou O, Maniadakis N. Quality of life measurement in patients with hypertension in Cyprus. Hellenic J

Cardiol. 2011 Sep-Oct;52(5):407-15.


Maniadakis N, Ekman M, Calvert MJ, Freemantle N, Karamalis M, Vardas P.Cost effectiveness of cardiac resynchronization therapy in Greece: an analysis based on the CArdiac

REsychronization in Heart Failure trial. Europace. 2011 Nov;13(11):1597-603. Epub 2011 Aug 6.


Boriani G, Burri H, Mantovani LG, Maniadakis N, Leyva F, Kautzner J, Lubinski A, Braunschweig F, Jung W, Lozano IF, Fattore G. Device therapy and hospital reimbursement

practices across European countries: a heterogeneous scenario. Europace. 2011 May;13 Suppl

2:ii59-65.


Fattore G, Maniadakis N, Mantovani LG, Boriani G. Health technology assessment: what is it? Current status and perspectives in the field of electrophysiology. Europace. 2011 May;13 Suppl

2:ii49-53.


Kautzner J, Bulkova V, Hindricks G, Maniadakis N, Della Bella P, Jaïs P, Kuck KH. Atrial fibrillation ablation: a cost or an investment? Europace. 2011 May;13 Suppl 2:ii39-43.


Maniadakis N, Vardas P, Mantovani LG, Fattore G, Boriani G. Economic evaluation in cardiology. Europace. 2011 May;13 Suppl 2:ii3-8.


Maniadakis N, Kourlaba G, Fragoulakis V. Self-reported prevalence of atherothrombosis in a general population sample of adults in Greece; a telephone survey. BMC Cardiovasc Disord.

2011 Apr 14;11:16.


Pallis A1, Tsiantou V, Simou E, Maniadakis N. Pharmacoeconomic considerations in the treatment of breast cancer. Clinicoecon Outcomes Res. 2010;2:47-61. Epub 2010 Jun 15.


Simou E, Tsimitselis D, Tsopanlioti M, Anastasakis I, Papatheodorou D, Kourlaba G, Gerasimos P, Maniadakis N. Early evaluation of an organised mammography screening program in Greece

2004-2009. Cancer Epidemiol. 2011 Apr 5. [Epub ahead of print]


Maniadakis N, Ekman M, Fragoulakis V, Papagiannopoulou V, Yfantopoulos J. Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension

in Greece.Eur J Health Econ. 2011 Jun;12(3):253-61. Epub 2010 Apr 22.


Maniadakis N, Fragoulakis V, Pallis A, Simou E. V Georgoulias. Economic Evaluation Docetaxel/Gemcitabine versus Vinorelbine/ Cisplatin combination as Front-line Treatment for

Patients with Advanced/Metastatic Non Small Cell Lung Cancer in Greece: A cost minimization

analysis.Ann Oncol. 2010 Jul;21(7):1462-7. Epub 2009 Dec 17.

- 17 -


Boriani G, Maniadakis N, Auricchio A, Vardas P. Health economics and outcomes research: a new challenge and field of action for the European Heart Rhythm Association. Europace. 2010

May;12(5):601-3. Epub 2010 Mar 10.


Simou E, Foundoulakis E, Kourlaba G, Maniadakis N. Factors associated with the use of preventive services by women in Greece. Eur J Public Health. 2010 Jul 22. [Epub ahead of print]


Simou E, Maniadakis N, Pallis A, Foundoulakis E, Kourlaba G. Factors associated with the use of pap smear testing in Greece. J Womens Health (Larchmt). 2010 Aug;19(8):1577-85.


Theodorou M, Samara K, Pavlakis A, Middleton N, Polyzos N, Maniadakis N. The public's and doctors' perceived role in participation in setting health care priorities in Greece. Hellenic J

Cardiol. 2010 May-Jun;51(3):200-8.


Theodorou M, Tsiantou V, Pavlakis A, Maniadakis N, Fragoulakis V, Pavi E, Kyriopoulos J. Factors influencing prescribing behaviour of physicians in Greece and Cyprus: results from a

questionnaire based survey. BMC Health Serv Res. 2009 Aug 20;9:150.


Theodoratou D, Maniadakis N, Fragoulakis V, Stamouli E. Analysis of published economic evaluations of angiotensin receptor blockers. Hellenic J Cardiol. 2009 Mar-Apr;50(2):105-18.

Review.


Maniadakis N, Fragoulakis V, Pectasides D, Fountzilas G. XELOX versus FOLFOX6 as an adjuvant treatment in colorectal cancer: an economic analysis. Curr Med Res Opin. 2009 Feb 12.


Andrikopoulos G, Tzeis S, Maniadakis N, Mavrakis HE, Vardas PE. Cost-effectiveness of atrial fibrillation catheter ablation. Europace. 2009 Feb;11(2):147-51.


Maniadakis N, Dafni U, Fragoulakis V, Grimani I, Galani E, Fragoulidi A & G Fountzilas. Economic Evaluation of Taxaned Based First Line Chemotherapy in The Treatment of Patients

With Metastatic Breast Cancer in Greece: An Analysis Alongside A Multicentre Randomised

Phase III Trial Annals of Oncology, 2009 Feb;20(2):278-85


Maniadakis N, Fragoulakis V, Pallis A, Simou E, Georgoulias V. Economic evaluation of docetaxel–gemcitabine versus vinorelbine–cisplatin combination as front-line treatment of

patients with advanced/metastatic nonsmall-cell lung cancer in Greece: a cost-minimization

analysis Annals of Oncology, Volume 21, Issue 7, 1 July 2010, Pages 1462–1467


Fountzilas G, Dafni U, Dimopoulos MA, Koutras A, Skarlos D, Papakostas P, Gogas H, Bafaloukos D, Kalogera-Fountzila A, Samantas E, Briasoulis E, Pectasides D, Maniadakis N,

- 18 -

Matsiakou F, Aravantinos G, Papadimitriou C, Karina M, Christodoulou C, Kosmidis P, & HP

Kalofonos A Randomised Phase III Study Comparing Three Anthracycline Free Taxane Based

Regimens, as First Line Chemotherapy in Metastatic Breast Cancer. A Hellenic Cooperative

Oncology Group study. Breast Cancer Research and Treatment, 2009 May;115(1):87-99. Epub

2008 May 16.


Maniadakis N, Kotsopoulos N, Prezerakos P & J Yfantopoulos. Health Care Services Performance Measurement: Theory, Methods and Empirical Evidence. European Research

Studies Journal, 2009, 12(3), 151-170


Spiraki C, Kaitelidou D, Papakonstantinou V, Prezerakos P & N Maniadakis. Health Related Quality of Life Measurement in Patients Admitted With Coronary Heart Disease and Heart

Failure in A Cardiology Department of A Secondary Urban Hospital in Greece. Hellenic Journal

of Cardiology, 2008, 49, 241-247


Al M, Maniadakis Ν, EWM, Grijseels & J Matthijs. Costs and Effects of Celecoxib and NSAID-Based Treatments for Patients With Rheumatoid Arthritis and Osteoarthritis in the Netherlands.

Value Health. 2008 Jul-Aug;11(4):589-99. Epub 2008 Jan 8.


Maniadakis N, Kotsopoulos Ν, Prezerakos P & J Yfantopoulos. Measuring Intra-Hospital Clinic Efficiency and Productivity: An Application to a Greek University General Hospital. European

Research Studies Journal, 2008, 11(1-2) 95-110


Prezerakos P, Maniadakis N, Kaitelidou D, Kotsopoulos N & J Yfantopoulos. Measuring Across Hospital Efficiency and Productivity: The Case of Second Regional Health Authority of

Attica. European Research Studies Journal, 2007, 10 (1-2), 83-96


Maniadakis N, Fragoulakis V, Pallis A, Prezarakos P & V Georgoulias. Economic Evaluation of First Line Treatment in Metastatic Colorectal Cancer (MCC). Economic analysis of a

multicenter, randomized, phase III trial comparing Irinotecan, Oxaliplatin, Folinic acid

(FOLFOXIRI), and 5-fluorouracil (FOLFIRI) with Irinotecan, Folinic acid, and 5-fluorouracil in

patients with metastatic colorectal cancer in Greece, Journal of Current Medical Opinion 2007,

23:9, 2251-2257


Maniadakis N, Fragoulakis V, Pallis A, Prezarakos P & V Georgoulias. Economic Evaluation of Docetaxel/Gemcitabine versus Docetaxel as Frontline Treatment of Patients with

Advanced/Metastatic Non Small Cell Lung Cancer in Greece. Lung Cancer, 2007, 58:2, 275-281


Maniadakis N, Tzanakis N, Fragoulakis V, Hatzikou M & Ν Siafakas. Economic Evaluation of Tiotropium and Salmeterol in the Treatment of Chronic Obstructive Pulmonary Disease (COPD)

in Greece. Current Medical Research and Opinion, 2006, 22:8, 1599-1607.


- 19 -

Fountzilas G, Papakostas P, Dafni U, Makatsoris T, Karina M, Kalogera-Fountzila A, Maniadakis N, et al.Paclitaxel and Gemcitabine Vs Paclitaxel and Pegylated Liposomal Doxorubicin in

Advanced Non – Nasopharyngeal Head and Neck Cancer. An Efficacy and Cost Analysis

Randomized Study Conducted by the Hellenic Cooperative Oncology Group. Annals of

Oncology, 2006, 17:10, 1560-1567


Kaitelidou D, Zyrogianis P, Maniadakis N & L Liaropoylos. Economic Evaluation of Haemodialysis: Implications for Technology Assessment in Greece. International Journal of

Technology Assessment in Health Care, 2005, 21:1, 40-46


Kaitelidou D, Maniadakis N, Liaropoulos L, Ziroyannis P, Theodorou M, & O Siskou Implications of Haemodialysis Treatment on Employment Patterns and Everyday Life of Patients.

Dialysis & Transplantation, 2005, 34:3, 138-144


Maniadakis N, Kaitelidou D, Siskou O, Spinthouri M, Liaropoulos L, Fragoulakis B, Hatzikou M & D Alexopoulos. Economic Evaluation of Treatment Strategies for Patients Suffering Acute

Myocardial Infarction in Greece. Hellenic Journal of Cardiology, 2005, 46, 212-221


Foutzilas et al & N Maniadakis. Paclitaxel and Epirubicin Versus Paclitaxel and Carboplatin as First-Line Chemotherapy in Patients With Advanced Breast Cancer: A Phase III Study

Conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology, 2004, 34:1, 695-

702


Kaitelidou D, Zyrogianis P, Maniadakis N & L Liaropoylos. The Cost of Haemodialysis in Greece. Hippokratia, 2004, 8:2, 81-87

Impact Factor: -, Citations: 3.

Aristides M, Weston AR, FitzGerald P, Le Reun C & N Maniadakis. Patient Preference and Willingness-To-Pay for Humalog Mix25 Relative to Humulin 30/70: A Multi-Country

Application of Conjoint Analysis. Value Health, 2004, 7:4, 442-454


Schiller J, Tilden D, Aristides M, Lees M, Kielhorn A, Maniadakis N & S Bhalla Retrospective Cost Analysis of Gemcitabine in Combination With Cisplatin in Non-Small Cell Lung Cancer

Compared to Other Combination Therapies in Europe. Lung Cancer, 2004, 43:1, 101-112


Maniadakis N & E Thanassoulis. A Cost Malmquist Productivity Index. Special Issue: DEA and its Uses in Different Countries. European Journal of Operations Research, 2004, 154:2, 396-409


Aristides M, Lees M, Botwood N, McKendrick J, Stephenson DA & N Maniadakis. Economic Evaluation of Gemcitabine in the Treatment of Pancreatic Cancer in the UK. European Journal of

Health Economics, 2003, 4:3, 216-221.


- 20 -

Liu JLY, Maniadakis N, Gray A & M Rayner. The Economic Burden of Coronary Heart Disease in the UK. Heart, 2002, 88:6, 597-603


Lees M, Aristides M, Maniadakis N, McKendrick J, Botwood N & D Stephenson. Economic Evaluation of Gemzitabime Alone and in Combination With Cisplatin in the Treatment of Non-

Small Cell Lung Cancer. Pharmacoeconomics, 2002, 20:5, 325-337


Burke TA, Zabinski RA, Pettitt D, Maniadakis N, Maurath CJ & JL Goldstein. A Framework for Evaluating the Clinical Consequences of Initial Therapy With NSAIDs, NSAIDs Plus

Gastroprotective Agents, or Celecoxib in the Treatment of Arthritis. Pharmacoeconomics, 2001,

19:S1, 33-47


Pettitt D, Goldstein JL, McGuire Α, Schwartz S, Burke T & N Maniadakis. Overview of the Arthritis Cost Consequence Evaluation System (ACCES): A Pharmacoeconomic Model for

Celecoxib. Rheumatology, 2000, 39:2, 33-42

Impact Factor:- , Citations: 37.

Maniadakis N & E Thanassoulis. Assessing Productivity Changes in UK Hospitals Reflecting Technologies and Input Prices. Applied Economics, 2000, 32, 1575-1589


Maniadakis N & A Gray. Health Economics and Orthopaedics. Journal of Bone and Joint Surgery, (BR), 2000, 82:1, 2-8


Maniadakis N & A Gray. The Economic Burden of Back Pain in the UK. Pain, 1999, 84:1, 95-103.


Hollingsworth B, Dawson P & N Maniadakis. Efficiency Measurement of Health Care: A Review of Non-Parametric Methods and Applications. Journal of Health Care Management Science,

1999, 2:3, 161-172

Impact Factor: , Citations: 457.

Maniadakis N, Hollingsworth B & E Thanassoulis. The Impact of the Internal Market on Hospital Efficiency, Productivity and Service Quality, Special Issue: Strategic Issues in Health Care.

Journal of Health Care Management Science, 1999, 2:2, 75-85.


Hollingsworth B, Maniadakis N, & E Thanassoulis. Efficiency. Measured Response. Health Service Journal, 1999 Nov 25;109(5682):28-9.


5.3 ΑΡΘΡΑ ΣTA ΕΛΛΗΝΙΚΑ ΣΕ ΕΠΙΣΤΗΜΟΝΙΚΑ ΠΕΡΙΟΔΙΚΑ ΜΕ ΚΡΙΣΗ: (4)

Μανιαδάκης Ν, Φραγκουλάκης Β & Π Πρεζεράκος, Συγκριτικά Κόστη Νέων Τεχνολογιών Κοινωνία, Οικονομία και Υγεία, 2007, 5, 92-106

- 21 -

Καιτελίδου Δ, Λιαρόπουλος Λ, Σίσκου Ο, Θεοδώρου Μ, Ζηρογιάννης Π, Μανιαδάκης Ν, Παπακωσταντίνου Β & Π Πρεζεράκος. Οι Κοινωνικές συνέπειες της αιμοκάθαρσης στην ζωή των

ασθενών με χρόνια νεφρική ανεπάρκεια. Νοσηλευτική, 2007, 46, 246-255

Mανιαδάκης N, Kαιτελίδου Δ, Σίσκου Ο, Σπινθούρη Μ, Λιαρόπουλος Λ, Φραγκουλάκης Β, Χατζίκου Μ & Δ Αλεξόπουλος. Αξιολόγηση Θεραπευτικών Στρατηγικών Διαχείρισης Ασθενών με

Οξύ Έμφραγμα του Μυοκαρδίου στην Ελλάδα. Ελληνική Καρδιολογική Επιθεώρηση, 2005, 46, 212-

221

Μανιαδάκης Ν & Γ Υφαντόπουλος. Το Φαινόμενο της Προκλητής Ζήτησης Ιατρικών Υπηρεσιών. Αρχεία Ελληνικής Ιατρικής, 1996, 13:1, 1-11.

5.4 ΜΟΝΟΓΡΑΦΙΕΣ ΣΤΑ ΑΓΓΛΙΚΑ ΣΕ ΔΙΕΘΝΕΙΣ ΣΕΙΡΕΣ ΜΕ ΚΡΙΣΗ: (7)

Maniadakis N & M Rayner. Coronary Heart Disease Statistics - Economics Supplement. British Heart Foundation. London 1998, p.1-25.

Maniadakis N & E Thanassoulis. Changes in Productivity of a Sample of Scottish Hospitals: A Cost Index Approach. Research Paper No. 288. Research Bureau, Business School, University of

Warwick, Coventry, 1998, p.1-20.

Maniadakis N, Hollingsworth B & E Thanassoulis. The Impact of Policy Initiatives on Productive Performance. Research Paper No. 285. Research Bureau, Business School. University of

Warwick, Coventry, 1998, p.1-20.

Maniadakis Ν & Ε Thanassoulis. Indirect Productivity Measurement and its Decomposition. Research Paper No. 282. Research Bureau, Business School. University of Warwick, Coventry,

1997, p.1-19.

Maniadakis N & L Read. A Note on Malmquist Productivity Index. Research Paper No. 278 Research Bureau, Business School. University of Warwick, Coventry, 1997, p.1-24.

Maniadakis N & E Thanassoulis. A Cost Malmquist Type Productivity Index. Research Paper No 270. Research Bureau, Business School. University of Warwick, Coventry, 1997, p.1-22.

Maniadakis N & E Thanassoulis. A Malmquist Index Approach to Productivity Change Measurement Allowing for Allocative Inefficiency. Research Paper No 230. Research Bureau,

Business School. University of Warwick, Coventry, 1996, p.1-26.

5.5 ΚΕΦΑΛΑΙΑ ΣΕ ΕΛΛΗΝΙΚΑ ΒΙΒΛΙΑ: (3)

Μανιαδάκης Ν & Β Φραγκουλάκης. Οικονομική Αποτίμηση Των Ενδοσκοπικών Παροχών Υγείας. Β Λιάτσικος & J Stolzenburg. Ενδοαυλική Ουρολογία. Γκιούρδας Εκδοτική, Αθήνα

2006, 446-468

Μανιαδάκης Ν. Τα Οικονομικά της Υγείας από την Οπτική του Μάνατζερ. Κοινωνία και Υγεία. Εθνικό Ίδρυμα Ερευνών, Αθήνα 2005, σελ.75-92.

- 22 -

Mανιαδάκης Ν & Β Φραγκουλάκης. Ο Ρόλος της Φαρμακοοικονομίας στον Κύκλο Ζωής του Φαρμάκου. Μ Γείτονα eds. Οικονομική Αξιολόγηση Τεχνολογιών Υγείας: Φαρμακοοικονομία

και Λήψη Αποφάσεων.Εκδόσεις Πανεπιστημίου Θεσσαλίας, Βόλος 2004, σελ.125-140.

5.6 ΚΕΦΑΛΑΙΑ ΣΕ ΔΙΕΘΝΗ ΒΙΒΛΙΑ: (1)

Maniadakis Ν & Α Gray. Economic evaluation, P Pynsent, J Fairbank & A Carr. Oxford Textbook in Orthopaedics and Trauma. Oxford University Press 2002, p.18-29.

5.7 ΔΗΜΟΣΙΕΥΣΕΙΣ ΠΕΡΙΛΗΨΕΩΝ ΣΕ TOMOYΣ ΔΙΕΘΝΩΝ ΣΥΝΕΔΡΙΩΝ: (131)

Gourzoulidis G, Tzanetakos C, Ioannidis I, Tsapas A, Kourlaba G, Papageorgiou G, Maniadakis

N. Budget Impact Analysis of Empagliflozin for The Treatment of Patients with Type 2

Diabetes Melitus at an Increased Cardiovascular Risk in Greece. (PDB13, November 2017,

ISPOR 20th Annual European Congress, Glasgow, Scotland)

Gourzoulidis G, Kourlaba G, Petrakis D2, Souglakos I3, Pentheroudakis G2, Maniadakis N.

Budget Impact Analysis of Trifluridine and Tipiracil in The Treatment of Metastatic Colorectal

Cancer in Greece. (PCN66, November 2017, ISPOR 20th Annual European Congress, Glasgow,

Scotland)

Solakidi A1, Tzanetakos C1, Bilir SP2, Beaudet A3, Zervoudaki A4, Lamprou C4, Maniadakis N.

Budget-Impact of Selexipag for The Treatment of Pulmonary Arterial Hypertension (PAH) in

Greece. (PRS14, November 2017, ISPOR 20th Annual European Congress, Glasgow, Scotland)

Kourlaba G1, Gourzoulidis G1, Rasmussen E2, Kontodimas S3, Maniadakis N. Cost Effectiveness

of Ultrasound Screening for Cancer Patients, to Detect Asymptomatic Thrombosis. PMD85,

November 2017, ISPOR 20th Annual European Congress, Glasgow, Scotland)

Solakidi A1, Tzanetakos C1, Maniadakis N. Cost-Effectiveness Analysis of Apremilast for he

Treatment of Active Psoriatic Arthritis in Greece (PMS45, November 2017, ISPOR 20th Annual

European Congress, Glasgow, Scotland)

Solakidi A1, Tzanetakos C1, Maniadakis N. Cost-Effectiveness of Apremilast for The Treatment

of Moderate to Severe Psoriasis in Greece. (PSS16, November 2017, ISPOR 20th Annual


Gourzoulidis G1, Tzanetakos C2, Ioannidis I3, Tsapas A4, Kourlaba G1, Papageorgiou G5,

Maniadakis N. Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2

Diabetes Melitus at an Increased Cardiovascular Risk in Greece (PDB28, November 2017,

ISPOR 20th Annual European Congress, Glasgow, Scotland)

Vellopoulou K1, Kourlaba G2, Vagiona A3, Ntavelis A4, Maniadakis N. Cost-Effectiveness of

inpatient Rehabilitation Compared to Home Discharge Following Longer Stay in General or

Neurological Ward, After Admission for the First Ever Stroke in Greece. PHS49, November

2017, ISPOR 20th Annual European Congress, Glasgow, Scotland)

- 23 -

Gourzoulidis G1, Kourlaba G1, Giannoulia P2, Panagiotidis P3, Maniadakis N. Cost-Effectiveness

of Ponatinib in The Treatment of Patients With Accelerated or Blast Phase - Chronic Myeloid

Leukemia in Greece. (PCN136, November 2017, ISPOR 20th Annual European Congress,

Glasgow, Scotland)


of Ponatinib in The Treatment of Patients With Acute Lymphoblastic Leukemia With

Philadelphia Chromosome Positive (PH+ ALL), Suitable for Allogeneic Stem Cell Transplant, in

Greece (PCN149, November 2017, ISPOR 20th Annual European Congress, Glasgow, Scotland)


of Ponatinib in The Treatment of Patients With Chronic Phase Chronic Myeloid Leukemia in

Greece. (PCN129, November 2017, ISPOR 20th Annual European Congress, Glasgow, Scotland)

Solakidi A1, Tzanetakos C1, Beaudet A2, Zervoudaki A3, Lamprou C3, Maniadakis N. Cost-

Effectiveness of Selexipag for the Treatment of Pulmonary Arterial Hypertension(PAH) in

Greece. (PRS35, November 2017, ISPOR 20th Annual European Congress, Glasgow, Scotland)

Gourzoulidis G1, Vassilopoulos G2, Gialama F1, Kourlaba G1, Diamantogiannis F3, Maniadakis

N. . Economic Evaluation of Dasatinib Compared to Nilotinib as Second Line Treatment of

Chronic MYELOID Leukemia in Greece. (PCN174, November 2017, ISPOR 20th Annual


Vellopoulou K1, Kourlaba G1, Doupis J2, Maniadakis N. Economic Evaluation of Flash Glucose

Monitoring Compared to Self Monitoring for Blood Glucose for the Management of Patients

Receiving Intensive Insulin With Diabetes Type 1 and Type 2 in Greece. (PMD72, November

2017, ISPOR 20th Annual European Congress, Glasgow, Scotland)

Gourzoulidis G1, Kourlaba G1, Petrakis D2, Souglakos I3, Pentheroudakis G2, Maniadakis N.

Economic Evaluation of Trifluridine and Tipiracil in the Treatment of Metastatic Colorectal

Cancer in Greece. (PCN125, November 2017, ISPOR 20th Annual European Congress, Glasgow,

Scotland)

Gourzoulidis G1, Kourlaba G2, Stafylas P3, Giamouzis G4, Parisis J5, Maniadakis N. Association

Between Copayment, Medication Adherence and Outcomes in the Management of Patients With

Diabetes and Heart Failure. (PHS48, October 2016, ISPOR 19th Annual European Congress,

Vienna, Austria)

Mylonas C1, Aravantinos G2, Bamias A3, Kourlaba G4, Maniadakis N. Budget Impact Analysis of

Olaparib Use in Patients BRCA – MUTATED PSROC in Greece. (PCN68, October 2016, ISPOR

19th Annual European Congress, Vienna, Austria)

Maistreli S1, Kourlaba G2, Georgopoulos D3, Maniadakis N. Budget Impact Analysis of The

Incorporation of a Computerised Temperature Engagement System in the Treatment of

- 24 -

Therapeutic Hypothermia in Greece. (PHS152, October 2016, ISPOR 19th Annual European

Congress, Vienna, Austria)

Gourzoulidis G1, Kourlaba G2, Kakisis J3, Matsagkas M4, Giannakoulas G5, Gourgoulianis K6,

Vassilakopoulos T7, Arzoumanidou D8, Maniadakis N. Cost Effectiveness Analysis of

Rivaroxaban for Treatment of Deep Vein Thrombosisand Pulmonary Embolism n Greece.

(PRS32, October 2016, ISPOR 19th Annual European Congress, Vienna, Austria)

Tzanetakos C1, Bargiota A2, Kourlaba G3, Maniadakis N. . Cost-Effectiveness of Exenatide Once

Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type2 Diabetes in Greece.

(PDB41, October 2016, ISPOR 19th Annual European Congress, Vienna, Austria)

Tzanetakos C1, Kourlaba G2, Chatzikou M3, Antoniou C4, Ioannidis D5, Lefaki I6, Petridis A7,

Rigopoulos D8, Roussaki-Schulze A9, Sotiriadis D10, Maniadakis N. Cost-Effectiveness of

Secukinumab Compared With Ustekinumab and Etanercept for The Treatment of Moderate to

Severe Psoriasis in Greece. (PSS42, October 2016, ISPOR 19th Annual European Congress,

Vienna, Austria)

Stafylas P1, Farmakis D2, Kourlaba G3, Giamouzis G4, Chatzikou M5, Kossiva E6, Maniadakis N.

, Parissis J8 Cost-Utility Analysis of Sacutibril/Valsartan for the Treatment of Chronic Heart

Failure in Greece. (PCV102, October 2016, ISPOR 19th Annual European Congress, Vienna,

Austria)

Solakidi A1, Kourlaba G1, Kontovinis L2, Koutsoukos K3, Bournakis E4, Boutis A5, Syrios J6,

Tzovaras A7, Michailidi C8, Kalogeropoulou M8, Maniadakis N. Economic Evaluation of

Everolimus as Second-Line Treatment of Metastatic Renal Carcinoma in Greece. (PCN132,

October 2016, ISPOR 19th Annual European Congress, Vienna, Austria)

Mylonas C1, Aravantinos G2, Bamias A3, Kourlaba G4, Maniadakis N. Economic Evaluation of

Olaparib in Patients With BRCA – Mutated PSROC in Greece. (PCN134, October 2016, ISPOR

19th Annual European Congress, Vienna, Austria)

Mylonas C1, Kourlaba G2, Vernadaki A3, Kakouros M3, Maniadakis N. Economic Evaluation of

Paritaprevir/Ritonavir/Ombitasvir (PrO) for Patients With Genotype 4 HCV in Greece. (Pin63,



Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir (PrOD) for Patients With Genotype 1A HCV in

Greece. (Pin59, October 2016, ISPOR 19th Annual European Congress, Vienna, Austria)


Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir (PrOD) for Patients With Genotype 1B HCV in

Greece. (Pin61, October 2016, ISPOR 19th Annual European Congress, Vienna, Austria)

- 25 -

Mylonas C1, Kourlaba G2, Skroumpelos A3, Maniadakis N. Economic Evaluation of Pertuzumab

Neoadjuvant Treatment for Patients With Locally Advanced, inflammatory, ot Early Stage

HER2-Positive Breast Cancer in Greece. (PCN148, October 2016, ISPOR 19th Annual European

Congress, Vienna, Austria)

Maniadakis N. , Kourlaba G2, Zavali M1, Zampoulakis D3, Kourkouni E2, Mylonas C1 Factors

Affecting Pharmaceutical Expenditures: A Systematic Review & Economic Modelling for

Greece. (PHP103, October 2016, ISPOR 19th Annual European Congress, Vienna, Austria)

Maistreli S1, Kourlaba G2, Tzanetakos C2, Trontzas P3, Maniadakis N. The Clinical and

Pharmacoeconomic Value of Febuxostat for the Treatment of Persistent Hyperrucaemia: A

Systematic Literature Review. (PMS45, October 2016, ISPOR 19th Annual European Congress,

Vienna, Austria)

Kourlaba G1, Gialama F2, Vellopoulou K1, Tsioufis K3, Maniadakis N. The Clinical Value of

Olmesartan for he Treatment of Hypertensive Patients: A Systematic Review. (PCV19, October

2016, ISPOR 19th Annual European Congress, Vienna, Austria)

Maistreli S1, Gourzoulidis G2, Vellopoulou K3, Kourlaba G3, Maniadakis N. The Clinical,

Functional and Economic Benefits of Physical Rehabilitation: A Systematic Review. (PHS165,


Stafylas P1, Farmakis D2, Kourlaba G3, Aletras V4, Giamouzis G5, Tsarouhas K5, Zouka M6,

Maniadakis N. , Parissis J8 The Economic Burden of Heart Failure n Greece From a Social

Security System Perspective. (PCV60, October 2016, ISPOR 19th Annual European Congress,

Vienna, Austria)

Gialama F1, Kourlaba G2, Gourzoulidis G1, Tsioufis K3, Maniadakis N. The Economic Value of

Olmesartan for The Treatment of Hypertensive Patients: A Systematic Review. (PCV98, October

2016, ISPOR 19th Annual European Congress, Vienna, Austria)

Brixner D, Maniadakis N, Kaló Z, Hu S, Johnston A, Shen J, Wijaya KE. Application of multi-criteria decision analysis (MCDA) scoring as an HTA methodology for off-patent

pharmaceuticals (OPP) in emerging markets. (PHP4, September 2016, ISPOR 7th Asia-Pacific

Conference, Singapore)

Vellopoulou K, Kourlaba G, Maniadakis N, Vardas P. A literature review to evaluate the pharmacoeconomic value of ranolazine for the treatment of symptomatic chronic stable angina.

(PCV124, November 2015, ISPOR 18th Annual European Congress, Milan, Italy)

Stafylas P, Mavrodi A, Kourlaba G, Maniadakis N. 8c.06: Cost-Effectiveness of Two Single-Pill Triple Antihypertensive Therapies Based on the Ambulatory Blood Pressure Measurements. J

Hypertens 2015;33 Suppl 1:e111.

Tzanetakos C, Vassilopoulos D, Kourlaba G, Christou P, Maniadakis N. Budget impact analysis of certolizumab pegol for the treatment of active psoriatic arthritis in Greece. (PMS29, November

2015, ISPOR 18th Annual European Congress, Milan, Italy)

- 26 -

Relakis I, Patrikos D, Kourlaba G, Christou P , Maniadakis N. Budget impact analysis of certolizumab pegol in the treatment of axial spondyloarthritis in Greece. (PMS32, November

2015, ISPOR 18th Annual European Congress, Milan, Italy)

Kourlaba G, Gourzoulidis G, Aravantinos G, Athanasiadis I, Lyman GH, Villa G, Papagiannopoulou V, Tritaki G, Maniadakis N. Cost-effectiveness analysis of granulocyte

colony-stimulating factors for the prophylaxis of chemotherapy-induced febrile neutropenia in

patients with breast cancer in Greece. (PCN149, November 2015, ISPOR 18th Annual European

Congress, Milan, Italy)

Gourzoulidis G, Kourlaba G, Apostolidis J, Lyman GH, Villa G, Papagiannopoulou V, Tritaki G, Maniadakis N. Cost-effectiveness analysis of granulocyte colony-stimulating factors for the

prophylaxis of chemotherapy-induced febrile neutropenia in patients with non-hodgkin's

lymphoma in Greece. (PCN156, November 2015, ISPOR 18th Annual European Congress,

Milan, Italy)

Kourlaba G, Tzanetakos C, Datseris J, Rouvas A, Arzoumanidou D, Maniadakis N. Cost-effectiveness analysis of intravitreal aflibercept in the treatment of neovascular age-related

macular degeneration in Greece. (PSS33, November 2015, ISPOR 18th Annual European


Tzanetakos C, Tentolouris N, Kourlaba G, Maniadakis N. Cost-effectiveness of dapagliflozin as add-on to metformin for the treatment of type 2 diabetes in Greece. (PDB55, November 2015,

ISPOR 18th Annual European Congress, Milan, Italy)

Tzanetakos C, Vassilopoulos D, Kourlaba G, Christou P, Maniadakis N. Cost-utility analysis of certolizumab pegol for the treatment of active psoriatic arthritis IN GREECE. (PMS74,

November 2015, ISPOR 18th Annual European Congress, Milan, Italy)

Relakis I, Patrikos D, Kourlaba G, Christou P, Maniadakis N. Cost-utility of certolizumab pegol for the treatment of axial spondyloarthritis in Greece. (PMS60, November 2015, ISPOR 18th

Annual European Congress, Milan, Italy)

Kourlaba G, Relakis J, Mahon R, Kalogeropoulou M, Pantelopoulou G, Kousidou O, Maniadakis N. Cost-utility of ranibizumab versus aflibercept for treating visual impairment due to diabetic

macular edema in Greece. (PSS44, November 2015, ISPOR 18th Annual European Congress,

Milan, Italy)

Kourlaba G, Vlachopoulos C, Parissis J, Kanakakis J, Gourzoulidis G, Maniadakis N Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris

in Greece. (PCV122, November 2015, ISPOR 18th Annual European Congress, Milan, Italy)

Kourlaba G, Gourzoulidis G, Tsioufis K, Andrikopoulos G, Beletsi A, Maniadakis N. Economic evaluation of trimetazidine in the management of chronic stable angina in Greece .(PCV100,

November 2015, ISPOR 18th Annual European Congress, Milan, Italy)

Kourlaba G, Chatzikou M, Pantelopoulou G, Maniadakis N .Health and economic outcomes related to delay between medical indication and treatment with ranibizumab in age-related

macular degeneration in Greece .(PSS46, November 2015, ISPOR 18th Annual European


- 27 -

Cristino J, Diel I, Finek J, Perez Encinas M, Maniadakis N, Ikenberg R, Campos Tapias I, Jandova P, Zahn DP, Moser C, Bolognese L, Tritaki G, Gatta F, Hechmati G The clinical and

economic burden of skeletal related events in austria, czech republic, Germany, Greece, Italy,

Spain and Switzerland: a comparison between the use of denosumab and zoledronic acid in

patients with breast cancer and bone metastases. (PCN299, November 2015, ISPOR 18th Annual

European Congress, Milan, Italy)

Cristino J, Finek J, Maniadakis N, Perez Encinas M, Ikenberg R, Campos Tapias I, Jandova P, Zahn DP, Moser C, Bolognese L, Tritaki G, Gatta F, Hechmati G. The clinical and economic

burden of skeletal related events in austria, czech republic, Germany, Greece, Italy, Spain and

Switzerland: a comparison between the use of denosumab and zoledronic acid in patients with

prostate cancer and bone metastases. (PCN298, November 2015, ISPOR 18th Annual European


Fanourgiakis JA, Simantirakis E, Kanoupakis E, Chrysostomakis S, Maniadakis N, Kourlamba G, Vardas P. Annual medication cost attributed to each kind of treatment of patients subjected to

crmds implantation . (PCV62, May 2015, ISPOR 20th Annual International Meeting,

Philadelphia, PA, USA)

Fanourgiakis JA, Simantirakis E, Kanoupakis E, Chrysostomakis S, Maniadakis N, Kourlamba G, Vardas P. Cost attributed to productivity loss in patients subjected to pacemaker (PM) and

implantable cardioverter-defibrillator (ICD) implantation .(PMD53, May 2015, ISPOR 20th

Annual International Meeting, Philadelphia, PA, USA)

Tzanetakos C, Maniadakis N, Kourlaba G, Tzioufas A, Goules A, Theodoratou T, Christou P Budget impact analysis of certolizumab pegol in the management of patients with moderate-to-

severe active rheumatoid arthritis in Greece. (PMS15, November 2014, ISPOR 17th Annual

European Congress, Amsterdam, The Netherlands)

Kourlaba G, Boletis I, Goumenos D, Iatrou C, Papagiannopoulou V, Tritaki G, Maniadakis N Cost consequence analysis of darbepoetin alfa for the treatment of anemia due to chronic kidney

disease (CKD) in Greece. (PUK15, November 2014, ISPOR 17th Annual European Congress,

Amsterdam, The Netherlands)

Tzanetakos C, Melidonis A, Verras C, Kourlaba G, Maniadakis N.Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled type 2 diabetes

on oral antidiabetic drugs in Greece .(PDB74, November 2014, ISPOR 17th Annual European

Congress, Amsterdam, The Netherlands)

Kourlaba G, Boukovinas I, Saridaki Z, Papagiannopoulou V, Tritaki G, Maniadakis N. Cost - effectiveness analysis of PANITUMUMAB+MFOLFOX over BEVACIZUMAB+MFOLFOX as

a first-line treatment for metastatic colorectal cancer patients with wild-type ras Greece.(PCN110,

November 2014, ISPOR 17th Annual European Congress, Amsterdam, The Netherlands)

Kourlaba G, Palaka E, Papagiannopoulou V, Maniadakis N .Cost-effectiveness and cost-utility of granulocyte colony-stimulating factors in the primary prophylaxis of chemotherapy induced

febrile neutropenia (FN) in breast cancer patients in Greece: a comparative analysis .(PCN111,

November 2014, ISPOR 17th Annual European Congress, Amsterdam, The Netherlands)

Mylonas C, Kourlaba G, Fountzilas G, Skroumpelos A, Maniadakis N .Cost-minimization analysis of trastuzumab intravenous versus trastuzumab subcutaneous for the treatment of

patients with HER2+ early breast cancer and metastatic breast cancer in Greece

- 28 -

(PCN151, November 2014, ISPOR 17th Annual European Congress, Amsterdam, The

Netherlands)

Tzanetakos C, Maniadakis N, Kourlaba G, Tzioufas A, Goules A, Theodoratou T, Christou P Cost-utility analysis of certolizumab pegol plus methotrexate for the treatment of moderate-to-

severe active rheumatoid arthritis in Greece .(PMS54, November 2014, ISPOR 17th Annual


Mylonas C, Kourlaba G, Berberian K, Maniadakis N .Economic evaluation of ferric carboxymaltose in patients with chronic heart failure and iron deficiency: an analysis for Greece

based on FAIR-HF TRIAL .(PCV80, November 2014, ISPOR 17th Annual European Congress,


Fragoulakis V, Papakostas P, Pentheroudakis G, Dervenis C, Maniadakis N .Economic evaluation of nab-paclitaxel plus gemcitabine versus gemcitabine alone for the management of metastatic

pancreatic cancer in Greece .(PCN105, November 2014, ISPOR 17th Annual European Congress,


Relakis J, Paparrigopoulos T, Kourlaba G, Maniadakis N .Economic evaluation of nalmefene for the treatment of alcohol dependence in Greece .(PMH27, November 2014, ISPOR 17th Annual


Stafylas P, Mavrodi A, Kourlaba G, Hatzikou M, Rombopoulos G, Maniadakis N .Economic evaluation of valsartan versus olmesartan addition to amlodipine and hydrochlorothiaziade

single-pill triple antihypertensive therapy .(PCV99, November 2014, ISPOR 17th Annual

European Congress, Amsterdam, The Netherlands) pdf available

Relakis J, Kourlaba G, Maniadakis N. Simvastatin plus fenofibrate as a fixed dose combination in the treatment of mixed dyslipidaemia in Greece: Βudget impact analysis

(PCV41, November 2014, ISPOR 17th Annual European Congress, Amsterdam, The

Netherlands)

Simantirakis E, Fanourgiakis J, Kanoupakis E, Chrysostomakis S, Maniadakis N, Kourlaba G, Vardas P .Association between baseline socio-demographic and clinical characteristics and total

annual cost of patients subjected to CRMDS implantation .(PCV44, September 2014, ISPOR 6th

Asia-Pacific Conference, Beijing, China)

Fragoulakis V, Pescott C, Maniadakis N. Economic evaluation of in-vitro fertilization as assisted reproductive technique in management of infertility in the netherlands: a cost-effectiveness model

based on a long down-regulation protocol .(PIH32, May 2014, ISPOR 19th Annual International

Meeting, Palais des Congrès de Montréal)

Fanourgiakis J, Simantirakis E, Kanoupakis E, Chrysostomakis S, Maniadakis N, Kourlaba G, Vardas P. Follow up cost of patients subjected to crmd in Greece.(PCV97, May 2014, ISPOR

19th Annual International Meeting, Palais des Congrès de Montréal)

Fanourgiakis J, Simantirakis E, Kanoupakis E, Chrysostomakis S, Maniadakis N, Kourlaba G, Vardas P .Procedure (implantation) cost and total hospitalization cost of patients subjected to

cardiac rhythm management devices implantation: results from a single tertiary centre. (PCV99,

May 2014, ISPOR 19th Annual International Meeting, Palais des Congrès de Montréal) pdf

available

- 29 -

Pappa V, Fragoulakis V, Maniadakis N, Tsatalas C, Zikos P, Meletis J, Anagnostopoulos N, Anagnostopoulos A. Safety and tolerability of azacitidine in patients with intermidiate-2 and high

risk myelodysplastic syndromes in Greece: a retrospective chart review study for the daily

practise .(PSY12, May 2014, ISPOR 19th Annual International Meeting, Palais des Congrès de

Montréal)

Pappa V, Fragoulakis V, Maniadakis N, Briasoulis E, Tsionos K, Kioumi A, Vervesou E, Symeonidis A .The overall response rate of azacitidine in patients with intermidiate-2 and high

risk myelodysplastic syndromes: a retrospective chart review study from Greece .(PSY2, May

2014, ISPOR 19th Annual International Meeting, Palais des Congrès de Montréal)

Maniadakis N, Kourlaba G , Kapaki V, Damianidi L. A systematic review of the effect

ΒΙΟΓΡΑΦΙΚΟ ΣΗΜΕΙΩΜΑ...- 5 - 2. ΑΠΑΣΧΟΛΗΣΗ – ΔΙΟΙΚΗΤΙΚΗ...

Documents

Transcript of ΒΙΟΓΡΑΦΙΚΟ ΣΗΜΕΙΩΜΑ...- 5 - 2. ΑΠΑΣΧΟΛΗΣΗ – ΔΙΟΙΚΗΤΙΚΗ...